Cartesian Therapeutics To Participate In Upcoming Investor Conferences
- A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026 One-on-one and group investor meetings at Morgan Stanley's 24th Annual Healthcare Conference on Monday, September 14, 2026 A fireside chat at the H.C. Wainwright 28th Annual Global Investment Conference at 1:30 p.m. ET on Tuesday, September 15, 2026
Live webcasts of the fireside chats are expected to be accessible in the Events section of the Company's website at , where an archived replay of the events will also be available for a limited time.
About Cartesian Therapeutics
Cartesian Therapeutics is a late clinical-stage company pioneering cell therapy for the treatment of autoimmune diseases. The Company's lead asset, Descartes-08, is a CAR-T in Phase 3 clinical development for patients with generalized myasthenia gravis, Phase 2 clinical development in myositis, specifically dermatomyositis and antisynthetase syndrome, and in Phase 1/2 clinical development for pediatric autoimmune diseases, including juvenile dermatomyositis. For more information, please visit or follow the Company on LinkedIn or X, formerly known as Twitter.
Investor Contact
Megan LeDuc
Associate Director, Investor Relations
...
Media Contact
David Rosen
Argot Partners
...
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept any
responsibility or liability for the accuracy, content, images, videos,
licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright issues
related to this article, kindly contact the provider above.
Comments
No comment